HCA
TRDA icon

Harbor Capital Advisors’s Entrada Therapeutics TRDA Stock Holding History

Harbor Capital Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Buy
+18,175
New +$208K 0.02% 582
2025
Q3 		– Sell
-15,277
Closed -$103K – 1488
2025
Q2 		$103K Buy
15,277
+1,874
+14% +$15.1K ﹤0.01% 647
2025
Q1 		$121K Buy
+13,403
New +$167K 0.01% 645
2024
Q2 		– Sell
-14,543
Closed -$206K – 771
2024
Q1 		$206K Buy
+14,543
New +$206K 0.03% 593

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbor Capital Advisors's TRDA Position: Q1 2026 in Review

Harbor Capital Advisors opened a new position in Entrada Therapeutics (TRDA) in Q1 2026: 18,175 shares worth $229K. The stake represents 0.02% of the portfolio and ranks #582 among its holdings. This is a return to the name: Harbor Capital Advisors previously reported a position in TRDA as recently as Q2 2025.

Harbor Capital Advisors first reported a position in TRDA in Q1 2024 and has held it in 4 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Harbor Capital Advisors held 18,175 shares of Entrada Therapeutics worth $229K as of Q1 2026.
  • Entrada Therapeutics was a new Harbor Capital Advisors position in Q1 2026.
  • Entrada Therapeutics made up 0.02% of Harbor Capital Advisors's portfolio in Q1 2026, its #582 holding.
  • Harbor Capital Advisors first reported a position in Entrada Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.